This abstract has been withheld from publication due to its inclusion in the AACR-NCI-EORTC Molecular Targets Conference 2015 Official Press Program. It will be posted online at the time of its presentation in a press conference or in a session.
Citation Format: Jason Lickliter, Hui Gan, Tarek Meniawy, Jason Yang, Lai Wang, Lusong Luo, Michael Millward. Phase 1 study of a novel PARP1/2 selective inhibitor, BGB-290. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr PR11.
- ©2015 American Association for Cancer Research.